Abstracts Archive - Page 2203 of 2607 - ACR Meeting Abstracts

Abstract Number: 445 • 2014 ACR/ARHP Annual Meeting
Differing Specificities of Anticitrullinated Peptide/Protein Antibodies in Palindromic Rheumatism and Rheumatoid Arthritis: A Case-Control Study
Sonia Cabrera-Villalba¹, María José Gomara², Julio Ramirez¹, Georgina Salvador³, Virginia Ruiz-Esquide¹, M. Victoria Hernández¹, José Inciarte-Mundo¹, Andrea Cuervo¹, Celia Saura¹, Juan D. Cañete¹, Isabel Haro² and Raimon Sanmarti¹, ¹Arthritis Unit. Rheumatology Department, Hospital Clínic of Barcelona, Barcelona, Spain, ²Unit of Synthesis and Biomedical Applications of Peptides, IQAC-CSIC, Barcelona, Spain, ³Hospital Universitario Mutua Terrassa, Barcelona, Spain
Background/Purpose: Palindromic rheumatism (PR) may evolve to rheumatoid arthritis (RA), particularly in patients with citrullinated peptide/protein antibodies (ACPA), although a significant number of patients do…
Abstract Number: 444 • 2014 ACR/ARHP Annual Meeting
Evidence for Citrullination of the Nuclear Transciption Factor Inhibitor of DNA Binding 1 (Id1) in Rheumatoid Arthritis
Ray A. Ohara¹, Gautam Edhayan¹, Christine M. Ha¹, M. Asif Amin¹, Ali S. Arbab², Phillip L. Campbell³, David A. Fox¹ and Jeffrey H. Ruth¹, ¹Internal Medicine, Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, ²Georgia Regents University, Augusta, GA, ³Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI
Background/Purpose: Citrullination is a post-translational modification mediated by peptidyl arginine deiminase (PAD) enzyme in which arginine is converted to citrulline. Inhibitor of DNA binding 1…
Abstract Number: 443 • 2014 ACR/ARHP Annual Meeting
Sputum Anti-Citrullinated Protein Antibodies in Patients with Long Standing Rheumatoid Arthritis
Ari Polachek¹, Wilma Vree Egberts², Elizabeth Fireman³, Daphna Paran⁴, Ido Drokman⁵, Ilana Kaufman⁶, Irena Wigler⁷, Dan Caspi⁸, David Levartovsky⁹, Ger JM Pruijn¹⁰ and Ori Elkayam¹¹, ¹Rheumatology, Tel Aviv Medical Center, Tel Aviv, Israel, ²Radboud University Medical Centre, Nijmegen, Israel, ³Pulmonary and Allergic diseases, Tel-Aviv Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel, ⁴Rheumatology, Tel-Aviv Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel, ⁵Radiology, Sourasky Medical Center, Tel-Aviv, Israel, ⁶Sourasky Medical Center, Tel-Aviv, Israel, ⁷Department of Rheumatology, Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, ⁸Rheumatology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ⁹Rheumatology, Tel Aviv Medical Ctr, Tel Aviv, Israel, ¹⁰Department of Biomolecular Chemistry, Radboud University, Nijmegen, Netherlands, ¹¹Rheumatology, Tel-Aviv Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel
Background/Purpose: The lung has been implicated in the pathogenesis of rheumatoid arthritis (RA). The aim of this study was to evaluate the presence of autoantibodies…
Abstract Number: 442 • 2014 ACR/ARHP Annual Meeting
Anti-Carbamylated Protein Antibody Levels Are Elevated in Seropositive Rheumatoid Arthritis and Correlate with Anti-Sa/Citrullinated Vimentin Antibody Levels
Gregory J. Challener¹, Jonathan D. Jones², B. JoNell Hamilton¹, Gilles Boire³, Artur José de Brum-Fernandes⁴, Pierre Cossette⁵, Patrick Liang³, Ariel Masetto⁶, Nathalie Carrier⁷, Henri A. Ménard⁸ and William F.C. Rigby⁹, ¹Microbiology and Immunology, Geisel School of Medicine at Dartmouth College, Lebanon, NH, ²Rheumatology, Geisel School of Medicine at Dartmouth College, Lebanon, NH, ³Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, Canada, ⁴Médecine, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, Canada, ⁵Internal Medicine Departement, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, Canada, ⁶Rheumatology, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, Canada, ⁷Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, Canada, ⁸Rheumatology, Research Institute of the McGill University Health Center, Montreal, QC, Canada, ⁹Rheumatology; Microbiology and Immunology, Geisel School of Medicine at Dartmouth College, Lebanon, NH
Background/Purpose: Recent studies indicate that the breach of immune tolerance that occurs in rheumatoid arthritis (RA) extends beyond the citrullination of arginines (as recognized by…
Abstract Number: 441 • 2014 ACR/ARHP Annual Meeting
Arthritis Associated Autoantibodies in Non-Rheumatoid Arthritis Patients with Mucosal Inflammation
Koen M. J. Janssen¹, Menke J. de Smit², Elisabeth Brouwer³, Berber Doornbos-van der Meer³, Arie Jan van Winkelhoff^2,4, Arjan Vissink⁵, Josje Altenburg⁶, Nivine Levarht⁷, Marije K. Verheul⁷, Leendert A. Trouw⁷ and Johanna Westra³, ¹Department of Oral and Maxillofacial Surgery, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ²Center for Dentistry and Oral Hygiene, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ³Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ⁴Department of Medical Microbiology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ⁵Department of Oral and Maxillofacial Surgery, University Medical Center Groningen, University of Groningen, Groningen, Netherlands, ⁶Department of Pulmonary Diseases, Medical Center Alkmaar, Alkmaar, Netherlands, ⁷Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Rheumatoid arthritis (RA) associated autoantibodies, such as anti-citrullinated protein antibodies (ACPA), rheumatoid factor (RF) and anti-carbamylated protein antibodies (anti-CarP), can be present in serum…
Abstract Number: 440 • 2014 ACR/ARHP Annual Meeting
Comparison of C-Reactive Protein (CRP) and Erythrocyte Sedimentation Rate (ESR) with Estimated Glomerular Filtration Rate (eGFR) in Patients with Rheumatoid Arthritis (RA)
Ilias Oikonomopoulos¹ and John D. Carter², ¹Internal Medicine; Division of Rheumatology, University of South Florida Morsani College of Medicine, Tampa, FL, ²Internal Medicine; Division of Rheumatology, University of South Florida, Tampa, FL
Background/Purpose: It has previously been demonstrated that the ESR and CRP correlate in patients with RA but with a high degree of variability. Reasons for…
Abstract Number: 439 • 2014 ACR/ARHP Annual Meeting
The Anti-IL-6 Antibody Sirukumab Inhibits Vascular Inflammation in a Human Surrogate Model of Atherosclerosis
Ryan Feaver¹, Sol Collado², Stephen Hoang², Erica Berzin², Allison Armstrong³, Debbie Gardner⁴, Paul Fisher⁵, Hao Liu⁶, Aaron Mackey², David Manka², Brian Wamhoff², David Shealy⁴ and Brett Blackman², ¹HemoShear, LLC, Charlottesville, VA, ²HemoShear, LLC., Charlottesville, VA, ³HemoShear, LLC., Virginia, VA, ⁴Janssen Research & Development, LLC, Spring House, PA, ⁵Janssen Research & Development, LLC., Spring House, PA, ⁶Immunology Research, Janssen Research and Development, LLC., Spring House, PA
Background/Purpose: Rheumatoid arthritis (RA) and atherosclerosis are chronic inflammatory diseases that share many biological features. Prevalence of atherosclerosis is increased by approximately 2-fold in RA,…
Abstract Number: 458 • 2014 ACR/ARHP Annual Meeting
Meta-Analysis of Serious Infections with Tofacitinib and Biological Treatment in Rheumatoid Arthritis Clinical Trials
V. Strand¹, S. Ahadieh², J. French³, J. Geier⁴, S. Krishnaswami⁵, S. Menon⁵, T. Checchio², R. Riese⁶ and J. Gomez-Reino⁷, ¹Biopharmaceutical Consultant, Portola Valley, CA, ²Pharmacometrics, Pfizer Inc, Groton, CT, ³Metrum Research Group, Tariffville, CT, ⁴Pfizer Inc, New York, NY, ⁵Clinical Pharmacology, Pfizer Inc, Groton, CT, ⁶Pfizer Inc, Groton, CT, ⁷Hospital Clinico, Universitario de Santiago, Santiago, Spain
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Serious infection events (SIEs) have been reported in the tofacitinib…
Abstract Number: 457 • 2014 ACR/ARHP Annual Meeting
First Confirmation Data of Long Term Safety for Tocilizumab in Real-World Setting; 3 Year Follow-up Postmarketing Surveillance of 5573 Patients with Rheumatoid Arthritis in Japan
Kazuhiko Yamamoto¹, Hajime Goto², Kenzo Hirao³, Atsuo Nakajima⁴, Hideki Origasa⁵, Nobuhiro Takagi⁶, Minako Tomobe⁷ and Kyoichi Totsuka⁸, ¹Allergy & Rheumatology, Univ Tokyo Gr School of Med, Tokyo, Japan, ²Fukujuji Hospital, Tokyo, Japan, ³Heart Rhythm Center, Tokyo Medical and Dental University, Tokyo, Japan, ⁴Department of Rheumatology, Tokyo Metropolitan Police Hospital, Tokyo, Japan, ⁵Division of Biostatistics and Clinical Epidemiology, University of Toyama School of Medicine, Toyama, Toyama, Japan, ⁶Medical Science, Chugai Pharmaceutical, Tokyo, Japan, ⁷Pharmacovigilance, Chugai Pharmaceutical, Tokyo, Japan, ⁸Kitatama Hospital, Tokyo, Japan
Background/Purpose: To evaluate the long-term safety of tocilizumab (TCZ) for the treatment of rheumatoid arthritis (RA) in a real-world clinical setting in Japan. Methods: In…
Abstract Number: 456 • 2014 ACR/ARHP Annual Meeting
AAA-Atpase p97 Regulates Autophagy-Associated Cell Death in Arthritis
Masaru Kato¹, Kerstin Klein², Caroline Ospelt², Christoph Kolling³, Michihito Kono¹, Shinsuke Yasuda¹, Renate E. Gay⁴, Steffen Gay² and Tatsuya Atsumi¹, ¹Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan, ²Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland, ³Schulthess Clinic, Zurich, Switzerland, ⁴Center of Experimental Rheumatology, Zurich University Hospital, Zurich, Switzerland
Background/Purpose: Recently we described a hypersensitivity of rheumatoid arthritis synovial fibroblasts (RASF) compared to osteoarthritis synovial fibroblasts to autophagy under conditions of severe endoplasmic reticulum…
Abstract Number: 455 • 2014 ACR/ARHP Annual Meeting
Clinical and Tissue Specificity of Antibodies Against Carbamylated Proteins in Patients with Rheumatoid Arthritis
Antonio Gonzalez¹, Ariana Montes¹, Eva Perez-Pampin¹, Maria Dolores Boveda² and Juan J. Gomez-Reino^1,3, ¹Laboratorio Investigacion 10 and Rheumatology Unit, Instituto Investigacion Sanitaria- Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain, ²Laboratorio Metabolopatias, Insitituto Investigacion Sanitaria- Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain, ³Medicine, University of Santiago de Compostela, Santiago de Compostela, Spain
Background/Purpose Antibodies against carbamylated proteins (CarP) are a new type of autoantibodies specific of patients with rheumatoid arthritis (RA) relative to healthy controls, but their…
Abstract Number: 454 • 2014 ACR/ARHP Annual Meeting
The Specificity of Anti-Carbamylated Protein Antibodies for Rheumatoid Arthritis in a Setting of Early Arthritis
Jing Shi, H.W. van Steenbergen, J. a. B. van Nies, E.W.Nivine Levarht, Annette H. M. van der Helm- van Mil, Tom W. J. Huizinga, René E.M. Toes and Leendert A. Trouw, Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose Anti-carbamylated protein (anti-CarP) antibodies have been described in rheumatoid arthritis (RA) and arthralgia patients [1;2] and occur in subsets of the anti-CCP2 positive and…
Abstract Number: 452 • 2014 ACR/ARHP Annual Meeting
The Use of Multiplex Bead Array to Follow the Effect of Rituximab on IgG and IgA Serum Autoantibody Responses to Citrullinated Epitopes in Patients with Rheumatoid Arthritis
Geraldine Cambridge¹, Lauren J. Lahey², Maria J. Leandro¹, William H. Robinson² and Jeremy Sokolove², ¹Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom, ²VA Palo Alto Healthcare System and Stanford University, Palo Alto, CA
Background/Purpose The majority of patients with established Rheumatoid arthritis (RA) have autoantibodies against the Fc of IgG (Rheumatoid factors-RhF) and to citrullinated protein antigens (ACPAs).…
Abstract Number: 451 • 2014 ACR/ARHP Annual Meeting
The Association of Fine Specificities of Anti-Citrullinated Protein Antibodies (ACPA) with disease Severity in African-Americans with RA
Maria I. Danila¹, Richard Reynolds², Gordon Wu³, Hemant Tiwari³, William H. Robinson⁴, Jeremy Sokolove⁵, CLEAR Investigators² and S. Louis Bridges Jr.^2,6, ¹Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Birmingham, AL, ³Biostatistics, University of Alabama at Birmingham, Birmingham, AL, ⁴VA Palo Alto Health Care System and Stanford University, Palo Alto, CA, ⁵VA Palo Alto Healthcare System and Stanford University, Palo Alto, CA, ⁶Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: RA is characterized by the presence of autoantibodies to citrullinated proteins (ACPA) and joint damage. The role of fine specificities of ACPA in radiographic…
Abstract Number: 450 • 2014 ACR/ARHP Annual Meeting
The Mucosal Anti-Citrullinated Protein Antibody Response in Pre-Clinical Rheumatoid Arthritis
Anneke van der Horst¹, Ivy Y.K. Choi², Dirkjan van Schaardenburg³, D.M Gerlag², Paul Tak², Dörte Hamann¹ and Rogier M. Thurlings², ¹Sanquin Diagnostic Services, Amsterdam, Netherlands, ²Clinical Immunology & Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ³Dr Jan van Breemenstraat 2, Reade, Amsterdam, Netherlands
Background/Purpose Recent data suggest rheumatoid arthritis (RA) may originate from an autoimmune response in inflamed mucosa. RA is associated with gingival and airway inflammation and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].